Series B

Nasdaq-listed Society Pass is ditching its e-commerce roots for the AI gold rush. Is this a savvy M&A masterstroke or a risky gamble in a capital-heavy arena?

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

A key accelerator selection puts South Korean startup ALL CONEC and its AI-driven dental platform in the spotlight, backed by Oracle's cloud power.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.